SCHEMBL2357337

SCHEMBL2357337

CCCCCCOc1ccc(-c2nc(-c3ccc(C(=O)OC)cc3)co2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.51
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALPL P05186 1/20 0.49
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
PLA2G2A P14555 2/20 0.47
NPC1 O15118 2/20 0.47
LMNA P02545 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
PLA2G4B P0C869 1/20 0.47
TLR8 Q9NR97 1/20 0.47
PTPN11 Q06124 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12243294 1.00 RARB (0.51) RARBMAPTSMN1; SMN2ALPLTP53
SCHEMBL12243195 0.89 GAA (0.55) RARBSMN1; SMN2TP53TSHRNPC1
SCHEMBL16199805 0.89 RARB (0.53) RARBSMN1; SMN2TP53TSHRNPC1
SCHEMBL2362233 0.89 RARB (0.67) RARBSMN1; SMN2TP53TSHRNPC1
SCHEMBL2356522 0.89 RARB (0.67) RARBSMN1; SMN2TP53TSHRNPC1
SCHEMBL12243186 0.89 GAA (0.55) RARBSMN1; SMN2TP53TSHRNPC1
SCHEMBL12294464 0.88 RARB (0.52) RARBSMN1; SMN2TP53TSHRNPC1
SCHEMBL12243296 0.88 NPC1 (0.50) MAPTSMN1; SMN2TP53NPC1CYP1A2
SCHEMBL12243345 0.86 RARB (0.50) RARBSMN1; SMN2TP53TSHRNPC1
SCHEMBL12243098 0.84 RARB (0.47) RARBMAPTSMN1; SMN2TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
EP-2350119-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE Merlion Pharmaceuticals Pte Ltd. (SG) 2011-08-03 EP disclosed
WO-2010062264-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE MERLION PHARMACEUTICALS PTE LTD (SG) 2010-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 RARB 2792/4885MAPT 4432/4885SMN1; SMN2 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.